Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 10, 2014, Pages 1397-1408

  Gonzalez, Martha ^a   Goracci, Laura ^b   Cruciani, Gabriele ^b   Poggesi, Italo ^c  

^a Clinical Pharmacology   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Janssen Cilag SpA Italia   (Italy)

Author keywords

Child Pugh; Dosing recommendations; Hepatic impairment; Multivariate analysis; Pharmacokinetic determinants; Physiology based pharmacokinetic modeling

Indexed keywords

ABACAVIR; ALVIMOPAN; ANIDULAFUNGIN; ARGATROBAN; ARIPIPRAZOLE; ASENAPINE; ATOMOXETINE; AXITINIB; BORTEZOMIB; CASPOFUNGIN; CEFDITOREN; CINACALCET; CIPROFLOXACIN; CONIVAPTAN; CYCLOBENZAPRINE; DASATINIB; DILTIAZEM; DOCETAXEL; DOFETILIDE; DRONEDARONE; ELETRIPTAN; ENTACAPONE; ENTECAVIR; EPIRUBICIN; EPLERENONE; ERIBULIN; ERLOTINIB; ESCITALOPRAM; ESZOPICLONE; UNINDEXED DRUG; XENOBIOTIC AGENT;

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; HUMAN; LIVER DISEASE; LIVER FUNCTION; PLASMA PROTEIN BINDING; REVIEW; BIOAVAILABILITY; BIOLOGICAL MODEL; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHARMACOKINETICS;

BIOLOGICAL AVAILABILITY; HUMANS; LIVER DISEASES; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; PHARMACOKINETICS; XENOBIOTICS;

EID: 84907166904     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.952628     Document Type: Review

References (41)

1. Peters SA. Physiologically-based pharmacokinetic (PBPK) modeling and simulations: Principles, methods, and applications in the pharmaceutical industry. John Wiley & Sons, Hoboken, NJ; 2008
2. Luttringer O, Theil FP, Poulin P, et al. Physiologically based pharmacokinetic( PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 2003;92(10):1990-2007
3. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156(4):271-8
4. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)- infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138(2):513-21
5. Featherstone B. Causes of liver disease and dysfunction. In: North Lewis P, editor. Drugs and the liver. Pharmaceutical Press, London; 2008
6. U.S. Food and Drug Administration. Guidance for industry pharmacokinetics in patients with impaired hepatic function: Study design, data analysis, and impact on dosing and labeling, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research( CDER), Center for Biologics Evaluation and Research (CBER). 2003. Clinical Pharmacology. Available from: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm072123.pdf [Accessed 31 March 2014]
7. Chang Y, Burckart GJ, Lesko LJ, Dowling TC. Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. J Clin Pharmacol 2013;53:962-6
8. Edginton AN, Willmann S. Physiology-based simulation of a pathological condition. Prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 2008;47:743-52
9. Johnson TN, Boussery K, Rowkland-Yeo K, et al. A semimechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010;49:189-206
10. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73
11. Holt A, Smith A. An introduction to the anatomy of the liver. In: North Lewis P, editor. Drugs and the liver. Pharmaceutical Press, London; 2008
12. Vaghjiani S. Functions of the liver. In: North Lewis P, editor, Drugs and the liver. Pharmaceutical Press, London; 2008
13. Hughes C. Assessing liver function. In: North Lewis P, editor, Drugs and the liver. Pharmaceutical Press, London; 2008
14. Child CG, Turcotte JC. Surgery and portal hypertension. Major Probl Clin Surg 1964;1:1-85
15. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9
16. Patel H, Egorin MJ, Remick SC, et al. Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing. J Clin Oncol 2004;22(14S):6051
17. Dourakis SP. Drug therapy in liver diseases. Ann Gastroenterol 2008;21:215-17
18. Albarmawi A, Czock D, Gauss A, et al. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol 2013;77:190-9
19. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005;40:174-81
20. Ramanathan RK, Egorin MJ, Takimoto CHM, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: A study by the national Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008;26:563-9
21. Johnson TN, Thomson AH. Pharmacokinetics of drugs in liver disease. In: North Lewis P, editor, Drugs and the liver. Pharmaceutical Press, London; 2008
22. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-61
23. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 1999;37:399-431
24. Scheen AJ. Pharmacokinetics and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol 2014;10(6):839-57
25. Budingen FV, Gonzalez D, Tucker AN, Derendorf H. Relevance of liver failure for anti-infective agents: From pharmacokinetic alterations to dosage adjustments. Ther Adv Infect Dis 2014;2:17-42
26. Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: A summary. Oncologist 2007;12:1070-83
27. Bosilkovska M, Walder B, Besson M, et al. Analgesics in patients with hepatic impairment. Pharmacology and clinical implications. Drugs 2012;72:1645-69
28. Schlatter C, Egger SE, Tchambaz L, Krahenbuhl S. Pharmacokinetic changes of psychotropic drugs in patients with liver disease. Implications for dose adaptation. Drug Saf 2009;32:561-78
29. Branch RA. Drugs in liver disease. Clin Pharmacol Ther 1998;64:462-4
30. Spray JW, Willet K, Chase D, et al. Dosage adjustment for hepatic dysfunction based on Child Pugh scores. Am J Health Syst Pharm 2007;64:690-3
31. Le Couteur DG, Fraser R, Hilmer S, et al. The hepatic sinusoid in aging and cirrhosis. Clin Pharmacokinet 2005;44:187-200
32. Frye RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 2006;80:235-45
33. National Cancer Institute Daily Med. Available from: Http://dailymed.nlm.nih. gov/dailymed/about.cfm [Last accessed 5 March 2014]
34. Wold H. Estimation of principal components and related models by iterative least squares. In: Krishnaiah PR, editor, Multivariate analysis. Academic Press, NY, USA; 1966. p. 391-420
35. Cruciani G, Crivori P, Carrupt PA, Testa B. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach. J Mol Struct( Theochem) 2000;503:17-30
36. Varmuza K, Filzmoser P. Introduction to multivariate statistical analysis in chemometrics. CRC Press/Taylor & Francis, Boca Raton, Fla; 2009
37. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam a review of its pharmacological properties and therapeutic use. Drugs 1984;28:519-43
38. Piqué JM, Feu F, de Prada G, et al. Pharmacokinetics of omeprazole given by continuous intravenous infusiotients with varying degrees of hepatic dysfunction. Clin Pharmacokinet 2002;41:999-1004
39. Simonson SG, Martin PD, Mitchell P, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003;58:669-75
40. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25:2553-63
41. Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br J Clin Pharmacol 2002;53:13S-20S